What is the 13F Pro Quality Score for PVLA?

13F Pro ranks PALVELLA THERAPEUTICS, INC. (PVLA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PVLA's current score at https://13fpro.ai/research/PVLA (free sign-up required for the full ranking).

Which hedge funds own the most PVLA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PVLA include SUVRETTA CAPITAL MANAGEMENT,, First Light Asset Management,, BVF /IL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PVLA as soon as new 13F filings post.

Where does 13F Pro source PVLA data?

All PALVELLA THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. PALVELLA THERAPEUTICS, INC. files with the SEC under CIK 1583648. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PVLA in?

PALVELLA THERAPEUTICS, INC. (PVLA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PVLA research updated on 13F Pro?

PVLA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PALVELLA THERAPEUTICS, INC.(PVLA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1583648 PVLA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $46.3M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PVLA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PALVELLA THERAPEUTICS, INC. (PVLA), a Healthcare sector company. PVLA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $46.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), PALVELLA THERAPEUTICS, INC. reports net income of $-15.8M, free cash flow of $-10.9M. Top institutional holders of PVLA by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT,, First Light Asset Management,, BVF /IL, based on the most recent SEC filings. PVLA trades on the Nasdaq exchange and files with the SEC under CIK 1583648. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PVLA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PALVELLA THERAPEUTICS, INC. directly from SEC EDGAR.

Net Income

Q1 2026

$-15.8M

Free Cash Flow

Q1 2026

$-10.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY21 $31.4MFY22 $25.9MFY23 $42.8MFY25 —

Net Income

-323.2% YoY

$-41.7MFY 2025

FY21 $-45.7MFY22 $-33.3MFY23 $18.7MFY25 $-41.7M

Operating Income

-225.2% YoY

$-38.6MFY 2025

FY21 $-51.8MFY22 $-43.5MFY23 $-11.9MFY25 $-38.6M

EPS (Diluted)

-271.0% YoY

$-3.71FY 2025

FY21 $-0.71FY22 —FY23 $2.17FY25 $-3.71

Total Assets

+689.1% YoY

$59.6MFY 2025

FY21 $153.6MFY22 $95.5MFY23 $7.5MFY25 $59.6M

Op. Cash Flow

-82.5% YoY

$-25.0MFY 2025

FY21 $-7.7MFY22 $-59.9MFY23 $-13.7MFY25 $-25.0M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2019	FY 2016
Revenue	—	$42.8M +65.3%	$25.9M -17.6%	$31.4M -32.1%	$46.3M +693.7%	$5.8M
Net Income	$-41.7M -323.2%	$18.7M +156.2%	$-33.3M +27.2%	$-45.7M -79.6%	$-25.5M -11.7%	$-22.8M
Operating Income	$-38.6M -225.2%	$-11.9M +72.7%	$-43.5M +16.1%	$-51.8M -90.9%	$-27.2M -19.3%	$-22.8M
EPS (Diluted)	$-3.71 -271.0%	$2.17	—	$-0.71	—	—
Total Assets	$59.6M +689.1%	$7.5M -92.1%	$95.5M -37.8%	$153.6M +8.8%	$141.1M +302.4%	$35.1M
Operating Cash Flow	$-25.0M -82.5%	$-13.7M +77.1%	$-59.9M -682.4%	$-7.7M +85.4%	$-52.5M	—

AI Insight: PVLA Financial Trends

A Q1 2026 equity injection to $232M buys runway, but operating cash burn hit a record -$11M in the same quarter with zero revenue.

• Operating losses have worsened steadily from -$4M in Q2 2024 to -$15M in Q1 2026, signaling accelerating R&D spend.

• Equity surged from $28M in Q4 2025 to $232M in Q1 2026, suggesting a significant capital raise that extends the cash runway.

• The company has reported $0M revenue across every reported quarter from Q2 2024 through Q1 2026 — entirely pre-commercial.

⚠ Operating cash burn reached -$11M in Q1 2026 — the worst in the observed period — while equity of $232M is the only buffer.

⚠ Net income diverged sharply from operating income in Q2 2025 (-$1M vs. -$9M); monitor non-operating items driving these gaps.

⚠ At Q1 2026 burn rates, the $232M equity base faces meaningful depletion without a catalyst or revenue inflection.

AI Insight: PVLA Ratio Trends

PVLA remains deeply unprofitable with no margin or leverage data available, but return metrics show extreme volatility across recent quarters.

• ROE swung from -127.2% in Q2 2024 to -10.8% in Q2 2025, then collapsed to -181.7% in Q4 2025, signaling highly unstable earnings.

• ROA improved from -97.5% in Q3 2024 to -7.0% in Q2 2025, but deteriorated sharply to -85.4% in Q4 2025.

• TTM ROE of -21.2% and ROA of -18.7% suggest the four-quarter average is less extreme than the worst individual quarters.

⚠ OpMargin, NPM, and D/E are entirely absent — no visibility into operating losses or balance sheet leverage.

⚠ Q4 2025 ROE of -181.7% represents the worst quarterly reading in the dataset — monitor for one-off charges driving this spike.

⚠ ROIC data gaps in Q3 2025 and Q4 2025 limit trend continuity; Q1 2026 ROIC of -25.6% warrants close tracking.

Get alerted when PVLA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PALVELLA THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PVLA

SUVRETTA CAPITAL MANAGEMENT, LLC
$143.8M1,153,496 sh
First Light Asset Management, LLC
$122.3M980,758 sh
BVF INC/IL
$119.8M960,989 sh
Frazier Life Sciences Management, L.P.
$110.0M882,400 sh
BlackRock, Inc.
$85.6M686,853 sh
JENNISON ASSOCIATES LLC
$79.9M640,611 sh
VANGUARD CAPITAL MANAGEMENT LLC
$59.5M477,294 sh
STATE STREET CORP
$57.2M458,999 sh
FEDERATED HERMES, INC.
$54.0M433,015 sh
FRONTIER CAPITAL MANAGEMENT CO LLC
$46.6M374,035 sh

Fund	Value	Shares
SUVRETTA CAPITAL MANAGEMENT, LLC	$143.8M	1,153,496
First Light Asset Management, LLC	$122.3M	980,758
BVF INC/IL	$119.8M	960,989
Frazier Life Sciences Management, L.P.	$110.0M	882,400
BlackRock, Inc.	$85.6M	686,853
JENNISON ASSOCIATES LLC	$79.9M	640,611
VANGUARD CAPITAL MANAGEMENT LLC	$59.5M	477,294
STATE STREET CORP	$57.2M	458,999
FEDERATED HERMES, INC.	$54.0M	433,015
FRONTIER CAPITAL MANAGEMENT CO LLC	$46.6M	374,035

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PVLA on your watchlist

Track score changes the day PALVELLA THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PVLA a good stock to buy?

13F Pro's AI-powered analysis of PALVELLA THERAPEUTICS, INC. (PVLA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PVLA are available on the PVLA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PVLA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PVLA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PALVELLA THERAPEUTICS, INC.'s investment landscape.